Triazolam (Halcion)

Subscribe to Selected New Research on Triazolam

267 relevant articles (18 outcomes, 46 trials/studies) found for this Drug

Description: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Also Known As:

Halcion; Apo-Triazo; Apotex Brand of Triazolam; Gen-Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Greenstone Brand of Triazolam; Par Brand of Triazolam; Pharmacia Brand of Triazolam; Pharmacia Spain Brand of Triazolam; Roxane Brand of Triazolam; Schein Brand of Triazolam; Trilam; U-33,030; UDL Brand of Triazolam; Apo Triazo; Gen Triazolam; Triazolam Greenstone Brand; Triazolam Par Brand; Triazolam Roxane Brand; Triazolam Schein Brand; Triazolam UDL Brand; U 33,030; U33,030; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Benzazepines: 2

Benzodiazepines: 4052

Triazolam: 267

alpha-hydroxytriazolam: 1

4-hydroxytriazolam

Experts

1.	Mintzer, Miriam Z: 2 articles (06/2007 - 03/2003)
2.	Griffiths, Roland R: 2 articles (06/2007 - 03/2003)
3.	Beck, Mike: 1 article (10/2008)
4.	Drum, Melissa: 1 article (10/2008)
5.	Nusstein, John: 1 article (10/2008)
6.	Lindemann, Matthew: 1 article (10/2008)
7.	Reader, Al: 1 article (10/2008)
8.	Mitchell, Andrew R J: 1 article (09/2006)
9.	Fabian, Tanya J: 1 article (04/2006)
10.	Corey, Sharon E: 1 article (04/2006)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 08/01/1981 - "Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia." 05/01/1983 - "Overall, triazolam is an effective and safe compound for the symptomatic treatment of insomnia complaints." 08/01/1993 - "The authors examined sleep improvement in subjects with primary insomnia who received triazolam plus behavioral therapy (N = 8) or triazolam plus sleep-related information (N = 7)" 01/01/1991 - "Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia." 11/01/1983 - "A double-blind crossover study in 53 psychiatric outpatients compared the safety and efficacy of triazolam and placebo in relieving insomnia refractory to treatment with a tricyclic antidepressant" Order ALL the reference details at left...
2.	Substance-Related Disorders (Drug Abuse) 01/01/2001 - "In the third, rats were treated chronically three daily doses of triazolam (started by 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, simulating a form of drug abuse" 01/01/2000 - "In the third, rats were treated chronically with three daily doses of Triazolam (started with 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, representing a form of drug abuse" 02/01/1995 - "The two subjects who did not self-administer triazolam in preference to placebo also had lesser histories of drug dependence" 07/01/1999 - "The present study compared the acute subject-rated effects, performance-impairing effects, and abuse potential of zaleplon and triazolam, a triazolobenzodiazepine hypnotic, in 14 healthy volunteers with histories of drug abuse" 01/01/2000 - "In conclusion, chronic single daily dose treatment (representing normal use) produces tolerance to Triazolam effects on brain GABA levels, while chronic three daily doses administration (akin to drug abuse) causes a fall in GABA levels." Order ALL the reference details at left...
3.	Shock 04/01/2006 - "The main objective of the present study was to determine whether triazolam improved patient perception of the shock experience or altered patient memory of shock discomfort relative to placebo" 04/01/2006 - "Similarly, participants recalled less discomfort the morning after shock with triazolam than with placebo (t= 2.82, df = 11, P = 0.017)" 07/01/2004 - "In contrast, triazolam only decreased errors and enhanced acquisition in the presence of concurrent response-independent tail shock when compared to saline administration under this condition" 02/01/1999 - "Six monkeys discriminated 0.1 mg/kg of triazolam from vehicle under a fixed-ratio 5 (FR 5) schedule of stimulus-shock termination (SST)" 01/01/1995 - "Triazolam (0.01-0.1 mg/kg, s.c.), administered before training, attenuated the suppression of motility in the conditioned fear stress task in a dose-dependent manner, without affecting the sensitivity to an electric foot shock" Order ALL the reference details at left...
4.	Chronic Obstructive Pulmonary Disease (COPD) 10/01/1988 - "We conclude that single-night use of triazolam improved the quality and duration of sleep in patients with chronic obstructive pulmonary disease" 06/01/1993 - "Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease." 10/01/1988 - "Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease." 10/01/1988 - "We compared the effects of a placebo with 0.125 and 0.25 mg of triazolam (Halcion) on sleep quality, oximetry, and respiratory events during sleep in ten stable outpatients with chronic obstructive pulmonary disease" 05/01/1993 - "Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD." Order ALL the reference details at left...
5.	Pain (Aches) 04/01/2006 - "Our data indicate that oral triazolam is beneficial in decreasing pain and anxiety associated with self-activated atrial defibrillation" 01/01/1998 - "Triazolam improves sleep but fails to alter pain in TMD patients." 08/01/1997 - "CONCLUSIONS: These results indicate that sublingual triazolam results in greater anxiolytic activity and less pain perception than oral administration as a result of greater plasma drug levels and may be useful as an alternative for nonparenteral outpatient sedation." 08/01/1997 - "RESULTS: Sublingual triazolam resulted in significantly less anxiety and pain at 15 minutes intraoperatively than both oral triazolam and placebo (p < 0.05)" 04/01/2006 - "Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Flurazepam (Dalmane)
2.	Benzodiazepines
3.	Temazepam (Nocturne)
4.	zolpidem (Ambien)
5.	Hypnotics and Sedatives (Sedatives)
6.	Flunitrazepam (Rohypnol)
7.	zaleplon (Sonata)
8.	Nitrazepam (Serenade)
9.	zopiclone (Zop)
10.	Diazepam (Valium)

Related Therapies and Procedures

1.	Withholding Treatment
2.	Conscious Sedation
3.	Hypnosis (Mesmerism)
4.	Intravenous Anesthesia

Best Treatments:
Research Summary Report
on Sleep Initiation and Maintenance Disorders

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 299 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>